| Cover | May 16, 2022 |
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | This Current Report on Form 8-K/A (the “Amendment”) is being filed as an amendment to the Current Report on Form 8-K filed by Allarity Therapeutics, Inc. (the “Company”) on May 17, 2022 (the “Original 8-K”) reporting the Company’s financial and operational information for its fourth quarter and full fiscal year ended December 31, 2021, which were announced in a press release issued on May 16, 2022 and furnished with the Original 8-K as Exhibit 99.1 (the “Original Press Release”). The Original Press Release contained an incorrect reference to “$971 million” instead of “$971 thousand” in reference to the size of a certain debt cancellation. This Amendment is being filed solely to furnish the press release dated May 18, 2022 as Exhibit 99.1, which corrects the typographical error. Except as amended by this Amendment and Exhibit 99.1 hereto, all information set forth in the Original 8-K and corresponding exhibits remains unchanged. |
| Document Period End Date | May 16, 2022 |
| Entity File Number | 001-41160 |
| Entity Registrant Name | ALLARITY THERAPEUTICS, INC. |
| Entity Central Index Key | 0001860657 |
| Entity Tax Identification Number | 87-2147982 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 210 Broadway |
| Entity Address, Address Line Two | Suite 201 |
| Entity Address, City or Town | Cambridge |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 02139 |
| City Area Code | 401 |
| Local Phone Number | 426-4664 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | ALLR |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | false |
